Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

THERAPY OF ENDOCRINE DISEASE: Growth hormone replacement therapy in adults: 30 years of personal clinical experience

Publikation: Bidrag til tidsskriftReviewForskningpeer review

DOI

  1. A role for exogenous GLP-1 in the management of postprandial hypoglycaemia after Roux-en-Y gastric bypass?

    Publikation: Bidrag til tidsskriftKommentar/debatForskningpeer review

  2. Risk factors for hyperglycemia in pregnancy in the DALI study differ by period of pregnancy and OGTT time point

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. EJE PRIZE 2018: A gut feeling about glucagon

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  4. Safety and convenience of once-weekly somapacitan in adult GH deficiency: a 26-week randomized, controlled trial

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. SGLT2 inhibitors: Clinical benefits by restoration of normal diurnal metabolism?

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  1. Evaluation of Serum Insulin-like Factor 3 Quantification by LC-MS/MS as a Biomarker of Leydig Cell Function

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Luteinizing Hormone Receptor Is Expressed in Testicular Germ Cell Tumors: Possible Implications for Tumor Growth and Prognosis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Use of stored serum in the study of time trends and geographical differences in exposure of pregnant women to phthalates

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

The acute metabolic actions of purified human growth hormone (GH) were first documented in adult hypopituitary patients more than 50 years ago, and placebo-controlled long-term GH trials in GH-deficient adults (GHDA) surfaced in 1989 with the availability of biosynthetic human GH. Untreated GHDA is associated with excess morbidity and mortality from cardiovascular disease and the phenotype includes fatigue, reduced aerobic exercise capacity, abdominal obesity, reduced lean body mass, osteopenia and elevated levels of circulating cardiovascular biomarkers. Several of these features reverse and normalize with GH replacement. It remains controversial whether quality of life, assessed by questionnaires, improves. The known side effects are fluid retention and insulin resistance, which are reversible and dose dependent. The dose requirement declines markedly with age and is higher in women. Continuation of GH replacement into adulthood in patients with childhood-onset disease is indicated, if the diagnosis is reconfirmed. GH treatment of frail elderly subjects without documented pituitary disease remains unwarranted. Observational data show that mortality in GH-replaced patients is reduced compared to untreated patients. Even though this reduced mortality could be due to selection bias, GH replacement in GHDA has proven beneficial and safe.

OriginalsprogEngelsk
TidsskriftEuropean Journal of Endocrinology
Vol/bind179
Udgave nummer1
Sider (fra-til)R47-R56
ISSN0804-4643
DOI
StatusUdgivet - jul. 2018

ID: 56535544